Box 1.
We recommend initiation of lifelong ART for all patients diagnosed with HIV infection. The CD4 count and clinical stage of the patient should no longer be a consideration in the decision to start ART. |
For patients who are asymptomatic with CD4 > 350 cells/μL, additional time (weeks to a few months) can be spent counselling and preparing the patient for lifelong ART with good adherence before starting. In those with CD4 < 350 cells/μL (and especially < 200 cells/μL), or with clinical indication for starting, there should not be undue delay. |
Within ART programmes, it is important to factor in that the absolute benefit of ART is much greater at lower CD4 counts (there is a mortality benefit at CD4 < 350 cells/μL.10† Therefore, planners and clinicians should prioritise and fast-track those with low CD4 counts (especially < 200 cells/μL); this is particularly relevant where there are ART shortages or anticipated stock-outs. |
Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257–265. PMID: 20647201, http://dx.doi.org/10.1056/NEJMoa0910370